# Legacy asset

> Legacy asset is a VC fund in Mumbai backing Biotechnology, Software and Education. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Mumbai, India
- Total investments: 5
- Last investment: Aug 2025
- Lead investor: 0%
- Last updated: Aug 2026

Legacy asset is a VC fund in Mumbai focused on Biotechnology and Software. Legacy assets' prominent investment areas include biotech, government, and health tech, as well as investments in startups.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.6M–$11M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 40% |
| Software | 1 | 20% |
| Education | 1 | 20% |
| Electronics | 1 | 20% |
| Health Care | 1 | 20% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 80% |
| Seed | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Brandworks Technologies | Brandworks Technologies is a design-focused, tech-driven firm delivering smart, cost-effective OEM-ODM solutions | $11M | Series A | Aug 12, 2025 |  |
| Ahammune Biosciences | Ahammune Biosciences is an innovation-led drug discovery company started in 2016 which focuses on developing new treatment options for immune mediated diseases of the skin. Our current program is on the depigmenting disorder, Vitiligo. | $5M | Series A | Sep 25, 2024 |  |
| Mynvax | Mynvax is an Indian-based biotech startup that develops next-generation vaccines for influenza. In addition, the technology allows for very rapid, large-scale, and low-cost production of vaccines that could potentially be used to protect people when there is a pandemic.Mynvax, which was incubated at the Indian Institute of Science, was founded in2017 by Raghavan Varadarajan and Gautham Nadig. | $2.6M | Series A | May 24, 2024 |  |
| Cusmat | Cusmat enable organisations to assess, train, upskill, plan learning tracks for employees by using AR/VR cloud learning management systems. | $3.5M | Series A | Feb 07, 2023 |  |
| Ahammune Biosciences | Ahammune Biosciences is an innovation-led drug discovery company started in 2016 which focuses on developing new treatment options for immune mediated diseases of the skin. Our current program is on the depigmenting disorder, Vitiligo. |  | Seed | Apr 26, 2021 |  |

5 of 5 investments shown.

## Co-investors
- [Ideaspring Capital](https://shizune.co/investors/profile/ideaspring-capital) — VC Fund, 2 deals together
- [IAN Group](https://shizune.co/investors/profile/indian-angel-network) — VC Fund, 2 deals together
- [Arkam Ventures](https://shizune.co/investors/profile/arkam-ventures) — VC Fund, 1 deal together
- [Better Capital](https://shizune.co/investors/profile/better-capital) — VC Fund, 1 deal together
- [Cactus Partners](https://shizune.co/investors/profile/cactus-venture-partners) — VC Fund, 1 deal together
- [Capital 2B](https://shizune.co/investors/profile/capital-2b) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Titan Capital](https://shizune.co/investors/profile/titan-capital) — VC Fund
- [Inflection Point Ventures](https://shizune.co/investors/profile/inflection-point-ventures-d275) — VC Fund
- [Blume Ventures](https://shizune.co/investors/profile/blume-ventures) — VC Fund

## Featured in investor lists
- [Biotechnology VC Funds in India](https://shizune.co/investors/biotechnology-vc-funds-india)
- [Biotech VC Funds in India](https://shizune.co/investors/biotech-vc-funds-india)
- [Biotechnology Investors in India](https://shizune.co/investors/biotechnology-investors-india)
- [Biotech Investors in India](https://shizune.co/investors/biotech-investors-india)
- [Life Science Investors in India](https://shizune.co/investors/life-science-investors-india)
- [Life Science VC Funds in India](https://shizune.co/investors/life-science-vc-funds-india)

## FAQ

### What does Legacy asset invest in?

Legacy asset invests primarily in Biotechnology, Software and Education startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in India. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Legacy asset's check size?

Legacy asset typically joins rounds of $2.6M–$11M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Legacy asset participates in.

### When did Legacy asset last invest?

The most recent investment recorded for Legacy asset closed in Aug 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co